Suppr超能文献

短链脂肪酸直肠灌洗治疗左侧溃疡性结肠炎:一项随机、安慰剂对照试验。

Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial.

作者信息

Breuer R I, Soergel K H, Lashner B A, Christ M L, Hanauer S B, Vanagunas A, Harig J M, Keshavarzian A, Robinson M, Sellin J H, Weinberg D, Vidican D E, Flemal K L, Rademaker A W

机构信息

Evanston Hospital, Division of Gastroenterology, Evanston, Illinois 60201, USA.

出版信息

Gut. 1997 Apr;40(4):485-91. doi: 10.1136/gut.40.4.485.

Abstract

BACKGROUND

Short chain fatty acid (SCFA) deficiency is associated with colitis in animals and humans, and the mucosal metabolism of these compounds is decreased in ulcerative colitis.

AIMS

To assess the efficacy of topical SCFA treatment in ulcerative colitis.

PATIENTS AND METHODS

103 patients with distal ulcerative colitis were entered into a six week, double-blind, placebo controlled trial of rectal SCFA twice daily; patients who were unchanged on placebo were offered SCFA in an open-label extension trial.

RESULTS

Of the 91 patients completing the trial, more patients in the SCFA treated than in the placebo treated group improved (33% v 20%, p = 0.14, NS). Those on SCFA also had larger, but statistically non-significant, reductions in every component of their clinical and histological activity scores. In patients with a relatively short current episode of colitis (< 6 months, n = 42), more responded to SCFA than to placebo (48% v 18%, p = 0.03). These patients also had larger, but statistically non-significant, decreases in their clinical activity index (p = 0.08 v placebo). Every patient who improved used at least five of six of the prescribed rectal SCFA irrigations, whereas only 37% who did not improve were as compliant. In the open-label extension trial, 65% improved on SCFA; these patients also had significant reductions (p < 0.02) in their clinical and histological activity scores.

CONCLUSIONS

Although SCFA enemas were not of therapeutic value in this controlled trial, the results suggest efficacy in subsets of patients with distal ulcerative colitis including those with short active episodes. Prolonged contact with rectal mucosa seems to be necessary for therapeutic benefit.

摘要

背景

短链脂肪酸(SCFA)缺乏与动物和人类的结肠炎相关,且这些化合物的黏膜代谢在溃疡性结肠炎中降低。

目的

评估局部应用SCFA治疗溃疡性结肠炎的疗效。

患者和方法

103例远端溃疡性结肠炎患者进入一项为期六周的双盲、安慰剂对照试验,每日两次直肠给予SCFA;在安慰剂治疗无改善的患者进入开放标签延长试验接受SCFA治疗。

结果

在完成试验的91例患者中,接受SCFA治疗组比安慰剂治疗组改善的患者更多(33%对20%,p = 0.14,无统计学意义)。接受SCFA治疗的患者其临床和组织学活动评分的各项指标降低幅度更大,但无统计学意义。在当前结肠炎发作相对较短(<6个月,n = 42)的患者中,对SCFA有反应的患者比安慰剂更多(48%对18%,p = 0.03)。这些患者的临床活动指数降低幅度也更大,但无统计学意义(与安慰剂相比p = 0.08)。每例病情改善的患者至少接受了规定的六次直肠SCFA灌肠中的五次,而病情未改善的患者中只有37%如此依从。在开放标签延长试验中,65%的患者在接受SCFA治疗后病情改善;这些患者的临床和组织学活动评分也显著降低(p < 0.02)。

结论

尽管在该对照试验中SCFA灌肠无治疗价值,但结果提示对包括发作期短的患者在内的远端溃疡性结肠炎亚组患者有效。似乎需要与直肠黏膜长时间接触才能获得治疗益处。

相似文献

3
Short-chain fatty acid topical treatment in distal ulcerative colitis.
Aliment Pharmacol Ther. 1995 Jun;9(3):309-13. doi: 10.1111/j.1365-2036.1995.tb00386.x.
4
Histological changes in the colonic mucosa following irrigation with short-chain fatty acids.
Eur J Gastroenterol Hepatol. 1997 Feb;9(2):163-8. doi: 10.1097/00042737-199702000-00010.
6
Effects of short-chain fatty acids on the inflamed colonic mucosa.
Scand J Gastroenterol Suppl. 1997;222:53-7. doi: 10.1080/00365521.1997.11720719.
8
Short-chain fatty acids in ulcerative colitis.
Nutr Rev. 1998 Jan;56(1 Pt 1):17-24. doi: 10.1111/j.1753-4887.1998.tb01654.x.
9
Local short-chain fatty acids supplementation without beneficial effect on inflammation in excluded rectum.
Scand J Gastroenterol. 2000 Feb;35(2):184-9. doi: 10.1080/003655200750024371.

引用本文的文献

1
Linking Short-Chain Fatty Acids to Systemic Homeostasis: Mechanisms, Therapeutic Potential, and Future Directions.
J Nutr Metab. 2025 Jul 28;2025:8870958. doi: 10.1155/jnme/8870958. eCollection 2025.
2
Gut microbiota-derived short-chain fatty acids and their role in human health and disease.
Nat Rev Microbiol. 2025 May 13. doi: 10.1038/s41579-025-01183-w.
4
The Probiotic Strain TO-A Produces Butyrate by Utilizing Lactate and Acetate.
Int J Mol Sci. 2025 Mar 24;26(7):2951. doi: 10.3390/ijms26072951.
5
Engineered Probiotic-Based Biomaterials for Inflammatory Bowel Disease Treatment.
Theranostics. 2025 Feb 18;15(8):3289-3315. doi: 10.7150/thno.103983. eCollection 2025.
6
The role of short-chain fatty acid in metabolic syndrome and its complications: focusing on immunity and inflammation.
Front Immunol. 2025 Feb 7;16:1519925. doi: 10.3389/fimmu.2025.1519925. eCollection 2025.
8
Short-chain fatty acids: linking diet, the microbiome and immunity.
Nat Rev Immunol. 2024 Aug;24(8):577-595. doi: 10.1038/s41577-024-01014-8. Epub 2024 Apr 2.
9
A serine-conjugated butyrate prodrug with high oral bioavailability suppresses autoimmune arthritis and neuroinflammation in mice.
Nat Biomed Eng. 2024 May;8(5):611-627. doi: 10.1038/s41551-024-01190-x. Epub 2024 Apr 1.
10
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches.
Pharmacol Ther. 2024 Apr;256:108605. doi: 10.1016/j.pharmthera.2024.108605. Epub 2024 Feb 16.

本文引用的文献

1
Cortisone in ulcerative colitis; final report on a therapeutic trial.
Br Med J. 1955 Oct 29;2(4947):1041-8. doi: 10.1136/bmj.2.4947.1041.
2
Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial.
Aliment Pharmacol Ther. 1996 Oct;10(5):729-36. doi: 10.1046/j.1365-2036.1996.d01-509.x.
3
Reducing sulfur compounds of the colon impair colonocyte nutrition: implications for ulcerative colitis.
Gastroenterology. 1993 Mar;104(3):802-9. doi: 10.1016/0016-5085(93)91016-b.
5
Budesonide for inflammatory bowel disease. Is it a magic bullet?
N Engl J Med. 1994 Sep 29;331(13):873-4. doi: 10.1056/NEJM199409293311311.
7
8
Short-chain fatty acid topical treatment in distal ulcerative colitis.
Aliment Pharmacol Ther. 1995 Jun;9(3):309-13. doi: 10.1111/j.1365-2036.1995.tb00386.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验